Last reviewed 2026-04-23 · How we verify

Placebo to CMS

This is a placebo control used in clinical trials and does not have an active pharmaceutical mechanism.

At a glance

Mechanism of action

Placebo serves as the control arm in phase 3 clinical trials to establish efficacy and safety of an investigational drug by comparison. It contains no active pharmaceutical ingredient and relies on the placebo effect and natural disease progression to establish a baseline for comparison against the active treatment arm.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease (PHASE1, PHASE2)
• Phase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia (PHASE2)
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis (PHASE2)
• A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants (PHASE1)
• A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis (PHASE2, PHASE3)
• A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) (PHASE1)
• tDCS and Cognitive Training in Active Duty Service Members With Mild TBI: A Pilot Study (NA)
• Colistin Methanesulfonate Sodium Inhalation for Prophylaxis of Ventilator-Associated Pneumonia (CIVAP): A Prospective, Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.